|Nice!||cjstocksup||11/10/22 9:52 PM|
|Closed $12.80 aftermarket. up 3% and just under||subslover||11/10/22 8:23 PM|
|Holding perfect.||cjstocksup||11/10/22 2:52 PM|
|Very little profit taking. She could take off||subslover||11/10/22 10:10 AM|
|If I am awake, I begin looking at||cjstocksup||11/09/22 7:58 PM|
|Hey buddy! Totally agree, I will be up||subslover||11/09/22 7:42 PM|
|I had to leave a bit early today||cjstocksup||11/09/22 7:38 PM|
|Not a bad day's pay! GLTY||subslover||11/09/22 6:56 PM|
|Not a bad day's pay! GLTY||subslover||11/09/22 6:56 PM|
|Yeah know his theory’s… indeed very interesting. But||europtiger||11/09/22 3:27 PM|
|THANKS!! (Austria?? In passing, G.W.F. HEGEL was BEST||Invest-in-America||11/09/22 3:23 PM|
|That’s how it is… not to sure about||europtiger||11/09/22 3:16 PM|
|EXACTLY!! Simply launch your buy, then go shopping||Invest-in-America||11/09/22 3:15 PM|
|Yeah I do like the tool of a||europtiger||11/09/22 3:03 PM|
|Very SMART way to do it, Dude! (That stop-loss.)||Invest-in-America||11/09/22 3:02 PM|
|Hoping for a squeeze… but as I did||europtiger||11/09/22 2:58 PM|
|GOOD!!||Invest-in-America||11/09/22 2:56 PM|
|1k Buddy||europtiger||11/09/22 2:52 PM|
|MACK: 1K shares, or $1K bucks worth, Bro???||Invest-in-America||11/09/22 2:51 PM|
|One man show here haha just bought 1K||europtiger||11/09/22 2:28 PM|
|MACK: I feels like old John-The-Baptist !!! Screamin||Invest-in-America||11/09/22 1:32 PM|
|MACK: The ONLY stock holding STRONG on this||Invest-in-America||11/09/22 12:12 PM|
|MACK: Buckle-up, my MACK Home-Boys, Home-Girls, Road-Dogs, &||Invest-in-America||11/09/22 11:30 AM|
|MACK: Look out, old 'MACKY' is back!!! "When||Invest-in-America||11/09/22 10:30 AM|
|MACK: Garyst!!! Where are ya, Homeboy??????||Invest-in-America||11/09/22 10:22 AM|
|MACK: I'm in!! God help us all!!! To||Invest-in-America||11/09/22 10:20 AM|
|MACK: Maybe the late Steve Jobs wishes he||Invest-in-America||11/09/22 9:58 AM|
|MACK: Rollin' like a 'Mack Truck'!!! WHAT?????||Invest-in-America||11/09/22 9:53 AM|
|MACK Looking like a runaway freight train||subslover||11/09/22 5:50 AM|
|Nice action today! I wonder if there is||fsulevine||01/11/22 12:56 PM|
|Merrimack sold its oncology portfolio to Ipsen in||lecorb||12/03/20 6:23 PM|
|Alright so we aren’t looking at any exponential||Clockonthewall||12/03/20 1:13 PM|
|https://www.google.com/amp/s/seekingalpha.com/amp/news/3640924-merrimack-pharma-||Clockonthewall||12/03/20 1:08 PM|
|Can you post that full link? When are||Clockonthewall||12/03/20 1:03 PM|
|If you receive that amount of money, you||lecorb||12/03/20 11:10 AM|
|Let’s stop the selling people||YachtClub||12/03/20 8:20 AM|
|Thank you. That is basically the info I||fsulevine||12/03/20 7:28 AM|
|Did u see the options on this ...||stock1ace1||12/02/20 10:51 PM|
|$MACK:Merrimack sold its oncology portfolio to Ipsen in||lecorb||12/02/20 9:56 PM|
|Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) was the recipient of||lecorb||12/02/20 9:42 PM|
|* * $MACK Video Chart 12-02-2020 * *||ClayTrader||12/02/20 5:34 PM|
|Unless I found the wrong one, all I||fsulevine||12/02/20 4:17 PM|
|Cool, thank you for the info! Will have||fsulevine||12/02/20 3:47 PM|
|SEC filing 13D > out an hour ago!||crudeoil24||12/02/20 3:18 PM|
|Anybody have an idea regarding the price movement||fsulevine||12/02/20 3:09 PM|
|$MACK / #Merrimack #Pharmaceuticals #GoldenCross||TFMG||08/30/20 9:40 PM|
|News: $MACK Merrimack Pharmaceuticals Adopts Section 382 Net||whytestocks||12/03/19 5:31 PM|
|News: $MACK Merrimack Receives $5 Million Milestone Payment||whytestocks||12/03/19 3:45 PM|
|News: $MACK Merrimack Pharmaceuticals Announces Per Share Amount||whytestocks||09/05/19 2:50 PM|
|News: $MACK Merrimack Declares $20 Million Special Dividend||whytestocks||07/25/19 2:00 PM|
Robert J. Mulroy has served as our President and Chief Executive Officer and a member of our board of directors since May 1999. Prior to joining us, Mr. Mulroy worked as a management consultant in the pharmaceutical and healthcare industries. Mr. Mulroy has also worked as a consultant in the field of international development and has served as an advisor to multiple start-up companies in the biotechnology industry. Mr. Mulroy holds a master’s degree in public and private management from Yale University and a BA from Stanford University.
Yasir B. Al-Wakeel, BM BCh, has served as our Chief Financial Officer and Head of Corporate Development since August 2015. Dr. Al-Wakeel previously served in various capacities at Credit Suisse, an investment bank, from January 2008 to June 2015. While at Credit Suisse, Dr. Al-Wakeel was most recently a Director of Healthcare Investment Banking focused on biotechnology and, prior to that role, he was an Equity Research Analyst covering the biotechnology and specialty pharmaceuticals sectors. Before joining Credit Suisse, Dr. Al-Wakeel was a practicing physician, holding both clinical and academic medical posts. Dr. Al-Wakeel holds a BM BCh (Doctor of Medicine) from Oxford University, an MA in theology from Cambridge University and a BA from Cambridge University.
Peter N. Laivins has served as our Head of Development since May 2014. Mr. Laivins served as our Vice President of Clinical Development from October 2011 to May 2014. Previously, Mr. Laivins ran an independent consulting practice specializing in oncology and neuroscience from January 2010 to October 2011. Prior to that, Mr. Laivins served as Vice President of Strategic Marketing at Elan Corporation, plc, a biopharmaceutical company, from 2006 to January 2010. Mr. Laivins began his career at Pfizer Canada, joined Pfizer International in New York in 1995 and held positions of increasing responsibility at Pfizer Inc., culminating as Group Leader of Pfizer US Oncology Marketing until 2006. Mr. Laivins holds an MBA and a BS from McGill University.
Gavin MacBeath, PhD, is a founder of Merrimack and Head of Translational Medicine. Dr. MacBeath leads translational research and drives our innovative diagnostic programs, helping to ensure we get the right drug to the right patient at the right time. He is also a founder of Chestnut Pharmaceuticals, serves on the Scientific Advisory Board of Aushon Biosciences and is a Lecturer and Principal Investigator at Harvard Medical School. He joined Merrimack in 2009 after serving on the faculty in the Department of Chemistry and Chemical Biology at Harvard University for eight years where he focused on developing and applying protein microarray technology to facilitate basic research in the area of systems biology. Dr. MacBeath holds a Bachelors of Science from University of Manitoba, Canada, and a PhD in Macromolecular and Cellular Structure and Chemistry from The Scripps Research Institute in La Jolla, California.
William M. McClements has served as our Head of Corporate Operations since September 2011. Previously, Mr. McClements served as Chief Human Resources Officer of Integreon Managed Solutions, Inc., a global research and business services company, from May 2010 to September 2011. Prior to that, Mr. McClements served as Chief Operating Officer and a partner at Monitor Group, a global strategic advisory firm, where he worked from 1987 to May 2010. From September 2009 to March 2010, Mr. McClements also served as Acting President of Be the Change, Inc., a nonprofit focused on creating national issue-based campaigns. Mr. McClements holds an MBA from Harvard Business School and a BA from Williams College.
Birgit M. Schoeberl, PhD, has served as our Head of Discovery since January 2015. Dr. Schoeberl served as our Senior Vice President of Research from January 2014 to January 2015, as our Vice President of Research from October 2009 to January 2014 and in various other research roles since she joined us in 2003. Prior to joining us, Dr. Schoeberl was a post-doctoral fellow at the Massachusetts Institute of Technology, where she built some of the earliest computational models of signaling networks. Dr. Schoeberl holds a PhD in systems biology from the Max Planck Institute for Dynamics of Complex Technical Systems in Germany and an MS in chemical engineering from the University of Karlsruhe in Germany.
Edward J. Stewart has served as our Head of Commercial since December 2011. Mr. Stewart served as our Senior Vice President of Business Development from March 2009 to December 2011 and in various other business development roles since he joined us in 2001. Mr. Stewart began his career at KPMG Peat Marwick LLP in the life sciences strategy consulting group. Mr. Stewart holds an MBA from the Johnson Graduate School of Management at Cornell University and a BS from Bates College.
William A. Sullivan has served as our Head of Finance and Accounting since August 2015 and our Treasurer since February 2010. Mr. Sullivan served as our Chief Financial Officer from May 2011 to August 2015, as our Vice President of Finance from February 2010 to May 2011, and as our Controller from November 2007 to February 2010. Previously, Mr. Sullivan served as Corporate Controller of Vette Corp., a thermal management solutions company, from 2004 to 2007. Mr. Sullivan began his career at Arthur Andersen LLP, where he obtained his certified public accountant license. Mr. Sullivan holds an MBA and an MS in accounting from Northeastern University’s Graduate School of Professional Accounting and a BA from Williams College.
One Kendall Square
Building 700, Suite B7201
Cambridge, MA 02139